New hope for Hard-to-Treat gynaecological cancers: drug combo trial shows promise
NCT ID NCT04065269
First seen Feb 21, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This phase 2 trial tests a new drug (ceralasertib) alone or with either a PARP inhibitor (olaparib) or an immunotherapy (durvalumab) in 174 people with advanced gynaecological cancers that have returned. The study looks at how well these combinations shrink tumors, especially in patients with a specific gene change (ARID1A loss). The goal is to find better treatment options for these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNAECOLOGICAL CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College NHS Trust
London, United Kingdom
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Royal United Hospital
Bath, BA1 3NG, United Kingdom
-
The Beatson
Glasgow, United Kingdom
-
The Christie
Manchester, United Kingdom
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
University of Montreal Hospital Centre
Montreal, Quebec, H2X 3E4, Canada
-
Western General Hospital
Edinburgh, United Kingdom
Conditions
Explore the condition pages connected to this study.